A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient. A gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line. This gene shows no similarity to known sequences and belongs to a family of at least three genes. It is expressed by the original melanoma cells, other melanoma cell lines, and by some tumor cells of other histological types. No expression was observed in a panel of normal tissues. Antigen MZ2-E appears to be presented by HLA-A1; anti-MZ2-E CTLs of the original patient recognized two melanoma cell lines of other HLA-A1 patients that expressed the gene. Thus, precisely targeted immunotherapy directed against antigen MZ2-E could be provided to individuals identified by HLA typing and analysis of the RNA of a small tumor sample.

[1]  T. Boon,et al.  The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice , 1991, The Journal of experimental medicine.

[2]  P. Chomez,et al.  Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide , 1990, The Journal of experimental medicine.

[3]  C. Slingluff,et al.  Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. , 1990, Cancer research.

[4]  R. Fauchet,et al.  Presence on a human melanoma of multiple antigens recognized by autologous CTL , 1989, International journal of cancer.

[5]  T. Boon,et al.  Structure of the gene of tum− transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells , 1989, Cell.

[6]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[7]  C. Slingluff,et al.  The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. , 1989, Journal of immunology.

[8]  M. Frohman,et al.  Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Vogelstein,et al.  Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. , 1988, Cancer research.

[10]  P. Chomez,et al.  Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Lipman,et al.  Improved tools for biological sequence comparison. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Devos,et al.  Production of stable cytolytic T‐cell clones directed against autologous human melanoma , 1987, International journal of cancer.

[13]  S. Ferrone,et al.  Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. , 1986, Journal of immunology.

[14]  Y. Kan,et al.  Versatile cosmid vectors for the isolation, expression, and rescue of gene sequences: studies with the human alpha-globin gene cluster. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Boon,et al.  Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis , 1983, The Journal of experimental medicine.

[16]  C. Uyttenhove,et al.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression , 1983, The Journal of experimental medicine.

[17]  F. Grosveld,et al.  Isolation of transforming DNA by cosmid rescue. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Macdonald,et al.  Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors , 1981, The Journal of experimental medicine.

[19]  C. Uyttenhove,et al.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis , 1980, The Journal of experimental medicine.

[20]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.

[21]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.